Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | ALPL | P05186 | 11/20 | 0.65 |
| ▸ | MAPT | P10636 | 7/20 | 0.65 |
| ▸ | RAB9A | P51151 | 4/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | HPGDS | O60760 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL644346 | 0.81 | TP53 (0.65) | ALPLSMN1; SMN2HPGDS | |
| SCHEMBL25438769 | 0.80 | PLA2G10 (0.48) | GAAALPLMAPTLMNA | |
| SCHEMBL646099 | 0.80 | GAA (1.00) | GAAALPLMAPTRAB9APOLB | |
| Hydrochloric Acid SCHEMBL1314014 | 0.79 | GAA (0.97) | GAAALPLMAPTRAB9APOLB | |
| SCHEMBL4788746 | 0.79 | GAA (0.75) | GAAALPLMAPTRAB9APOLB | |
| SCHEMBL855912 | 0.78 | ALPL (0.76) | GAAALPLMAPTRAB9APOLB | |
| SCHEMBL1414008 | 0.78 | MAPT (1.00) | GAAALPLMAPTRAB9APOLB | |
| SCHEMBL2524441 | 0.78 | ALPL (0.76) | GAAALPLMAPTRAB9APOLB | |
| SCHEMBL2631731 | 0.78 | MAPT (1.00) | GAAALPLMAPTRAB9APOLB | |
| SCHEMBL643567 | 0.75 | GAA (0.65) | GAAALPLMAPTRAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095044-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | Sanford-Burnham Medical Research Institute California | 2012-04-19 | — | — | US | disclosed |
| EP-2433496-A1 | Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification | Burnham Institute for Medical Research (US) | 2012-03-28 | — | — | EP | disclosed |
| US-8119693-B2 | Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-02-21 | — | — | US | disclosed |
| EP-2164329-A2 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | The Burnham Institute for Medical Research (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20090156560-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-06-18 | — | — | US | disclosed |
| WO-2009017863-A2 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095044-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | ALPL, CNDP2, ALPI | GAA 40/4885ALPL 1/4885MAPT 3950/4885 |
| US-20090156560-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | ALPL, CNDP2, ALPI | GAA 40/4885ALPL 1/4885MAPT 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.